Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer

Gynecologic Oncology

Volumn 114, Issue 3, 2009, Pages 415-419

  Yen, Ming Shien ^a   Twu, Nae Fong ^a   Lai, Chiung Ru ^a   Horng, Huann Cheng ^a   Chao, Kuan Chong ^a   Juang, Chi Mou ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Intraperitoneal chemotherapy; Nomogram; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COLON RESECTION; CYTOREDUCTIVE SURGERY; DISCRIMINANT ANALYSIS; EPITHELIUM TUMOR; FEMALE; HUMAN; INTRAPERITONEAL CHEMOTHERAPY; MAJOR CLINICAL STUDY; METASTASIS; MORBIDITY; MULTIPLE CYCLE TREATMENT; NOMOGRAM; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROPORTIONAL HAZARDS MODELS;

EID: 67651175842     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.05.034     Document Type: Article

References (25)

1. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 351 (2004) 2519-2529
2. Howell S.B., Pfeifle C.L., Wung W.E., Olshen R.A., Lucas W.E., Yon J.L., et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med. 97 (1982) 845-851
3. Casper E.S., Kelsen D.P., Alcock N.W., and Lewis J.L. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat. Rep. 67 (1983) 235-238
4. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 (1996) 1950-1955
5. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
6. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
7. Howell S.B., Zimm S., Markman M., Abramson I.S., Cleary S., Lucas W.E., et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J. Clin. Oncol. 5 (1987) 1607-1612
8. Walker J.L., Armstrong D.K., Huang H.Q., Fowler J., Webster K., Burger R.A., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 100 (2006) 27-32
9. Marth C., Walker J.L., Barakat R.R., Casado A., Gadducci A., Miller B., et al. Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer 109 (2007) 645-649
10. Kattan M.W., Eastham J.A., Stapleton A.M., Wheeler T.M., and Scardino P.T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl. Cancer Inst. 90 (1998) 766-771
11. Hoang T., Xu R., Schiller J.H., Bonomi P., and Johnson D.H. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J. Clin. Oncol. 23 (2005) 175-183
12. Peeters K.C., Kattan M.W., Hartgrink H.H., Kranenbarg E.K., Karpeh M.S., Brennan M.F., et al. Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma. Cancer 103 (2005) 702-707
13. Sorbellini M., Kattan M.W., Snyder M.E., Reuter V., Motzer R., Goetzl M., et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J. Urol. 173 (2005) 48-51
14. Chi D.S., Palayekar M.J., Sonoda Y., Abu-Rustum N.R., Awtrey C.S., Huh J., et al. Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. Gynecol. Oncol. 108 (2008) 191-194
15. Clark T.G., Stewart M.E., Altman D.G., Gabra H., and Smyth J.F. A prognostic model for ovarian cancer. Br. J. Cancer 85 (2001) 944-952
16. Grambsch P.M., Therneau T.M., and Fleming T.R. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics 51 (1995) 1469-1482
17. Harrell F.E., Califf R.M., Pryor D.B., Lee K.L., and Rosati R.A. Evaluating the yield of medical tests. JAMA 247 (1982) 2543-2546
18. Yen M.S., Juang C.M., Lai C.R., Chao G.C., Ng H.T., Yuan C.C., et al. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int. J. Gynaecol. Obstet. 72 (2001) 55-60
19. Earle C.C., Schrag D., Neville B.A., Yabroff K.R., Topor M., Fahey A., et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J. Natl. Cancer Inst. 98 (2006) 172-180
20. Chan J.K., Kapp D.S., Shin J.Y., Husain A., Teng N.N., Berek J.S., et al. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet. Gynecol. 109 (2007) 1342-1350
21. Gordon A.N., Tonda M., Sun S., and Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol. 95 (2004) 1-8
22. Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A., et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin. Oncol. 26 (2008) 890-896
23. Eisenkop S.M., Friedman R.L., and Spirtos N.M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88 (2000) 144-153
24. Tay E.H., Grant P.T., Gebski V., and Hacker N.F. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet. Gynecol. 99 (2002) 1008-1013
25. Leitao M.M., Kardos S., Barakat R.R., and Chi D.S. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol. Oncol. 95 (2004) 181-188